By Nate Raymond | February 23, 20225:08 PM EST

(Reuters) – The U.S. Food and Drug Administration is suspending a memorandum of understanding (MOU) with states governing how compounding pharmacies’ drugs are sold interstate and will engage in a years-long rulemaking process to adopt a new one.

READ FULL STORY …

SOURCE: https://www.reuters.com/legal/litigation/fda-redo-key-compounding-pharmacy-policy-win-industry-2022-02-23/